# A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

Source: https://onco.cc/trials/nct07688187/  
OnCo record `nct07688187` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of 225Ac/64Cu-PD-32766 (CA9 theranostic pair) run by PeptiDream Inc., now recruiting.

## Summary

A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma is a phase 1 interventional study registered as NCT07688187 by PeptiDream Inc., with 60 participants planned, started 2026-07-07. Conditions recorded: Clear Cell Renal Cell Carcinoma. Interventions recorded: PD-32766D (a Copper-64 [64Cu] labeled peptide) and PD-32766T (an Actinium-225 [225Ac] labeled peptide).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07688187
- Phase: 1
- Setting: An Open-Label, Multicenter, Phase 1a/1b, Dose Escalation/Dose Expansion Clinical Trial of Theranostic Pair PD-32766D, a 64Cu-Labeled Peptide and PD-32766T, an 225Ac-Labeled Peptide Targeting Carbonic Anhydrase IX in Adult Participants With Relapsed or Refractory Clear Cell Renal Cell Carcinoma Who Have Progressed From or Could Not be Administered Due to Medical Unsuitability or Limited Access to All Standard of Care Therapies
- Sponsor: PeptiDream Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07688187: https://clinicaltrials.gov/study/NCT07688187

## Connected records

- cancers: [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/)
- drugs: [225Ac/64Cu-PD-32766 (CA9 theranostic pair)](https://onco.cc/drugs/pd-32766/)
- companies: [PeptiDream](https://onco.cc/companies/peptidream/)

---
JSON: https://onco.cc/api/v1/entities/nct07688187.json